KMT2A-Partial Tandem Duplication Associates With Leukemia Transformation in Myelodysplastic Syndrome
Clinical Lymphoma Myeloma and Leukemia · 2026-10 · 26 (10) · 689-697
DOI: 10.1016/j.clml.2026.07.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Zhao-Yu Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, C…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Myeloid-Lymphoid Leukemia Protein, Histone-Lysine N-Methyltransferase, Tandem Repeat Sequences. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Partial tandem duplication of KMT2A (KMT2A-PTD) is observed not only in acute myeloid leukemia (AML) but also in myelodysplastic syndrome (MDS), while the prognostic value of KMT2A-PTD in MDS needs to be clarified and the optimal therapies for these patients remains unclear. METHODS: In this study, we analyzed 137 MDS patients with KMT2A-PTD from our hospital (PKUPH cohort) and incorporated 2493 MDS patients from the International Working Group for Prognosis in MDS (IWG-PM) cohort, among whom 65 patients had KMT2A-PTD. RESULTS: MDS patients with KMT2A-PTD in IWG-PM cohort had significantly higher blast percentage and IPSS-R score than those without KMT2A-PTD. The 3-year cumulative incidence of leukemia transformation in MDS patients with KMT2A-PTD from both PKUPH and IWG-PM cohort was significantly higher than that in MDS patients without KMT2A-PTD (49.8% [95% CI, 38.6%-61.1%] vs. 19.3% [95% CI, 17.5%-21.2%], P < .001; 58.3% [95% CI, 43.1%-73.5%] vs. 19.3% [95% CI, 17.5%-21.2%], P < .001), respectively. Multivariate analysis in the IWG-PM cohort showed that KMT2A-PTD was an independent poor predictor for leukemia transformation (P < .001). None of co-occurring gene mutations significantly influenced the risk of leukemia transformation in MDS patients with KMT2A-PTD. A landmark analysis in PKUPH cohort suggested that allogenic hematopoietic stem cell transplantation (allo-HSCT) significantly reduced the cumulative incidence of leukemia transformation (P < .001) and the cumulative incidence of relapse (17.6% [95% CI, 5.1%-28.7%] vs. 100% [95% CI, 51.0%-100%], P < .001), respectively. CONCLUSION: KMT2A-PTD may identify a distinct MDS subgroup characterized by a high risk of leukemia transformation, and allo-HSCT could improve outcomes of MDS patients with KMT2A-PTD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China.
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China. Electronic address: qin2000@aliyun.com.
Zitieren
APA
Li, Z. Y., Xie, D. H., Chen, W. M., Wang, X., Li, L. D., Hao, Y., Li, J. Y., Zhao, X. S., Jiang, H., Jiang, Q., Huang, X. J., & Qin, Y. Z. (2026). KMT2A-Partial Tandem Duplication Associates With Leukemia Transformation in Myelodysplastic Syndrome. Clinical Lymphoma Myeloma and Leukemia, 26(10), 689-697. https://doi.org/10.1016/j.clml.2026.07.008
Vancouver
Li ZY, Xie DH, Chen WM, Wang X, Li LD, Hao Y, et al. KMT2A-Partial Tandem Duplication Associates With Leukemia Transformation in Myelodysplastic Syndrome. Clinical Lymphoma Myeloma and Leukemia. 2026;26(10):689-697. doi:10.1016/j.clml.2026.07.008
BibTeX
@article{Li2026,
author = {Li, Zhao-Yu and Xie, Dai-Hong and Chen, Wen-Min and Wang, Xu and Li, Ling-Di and Hao, Yue and Li, Jin-Ying and Zhao, Xiao-Su and Jiang, Hao and Jiang, Qian and Huang, Xiao-Jun and Qin, Ya-Zhen},
title = {KMT2A-Partial Tandem Duplication Associates With Leukemia Transformation in Myelodysplastic Syndrome},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {10},
pages = {689--697},
doi = {10.1016/j.clml.2026.07.008}
}
EUVIMED